Description
DabrafenibisareversIBLekinaseinhibitorwithanticancerchemotherapeuticactivity.Thiscompoundisselectiveprimarilyformutant(V600E)B-Raf,buthasalsoinhibitedtumorgrowthincellsexpressingotherB-Rafmutants(V600K,V600D)andWTB-Raf.Dabrafenibispartiallyactiveagainstc-Rafaswell.DabrafenibisanATP-competitiveinhibitorthathasbeenapprovedforclinicaluseinthetreatmentofunresectableormetastaticmelanomas;itisalsobeingexaminedfortreatmentofbrainmetastasesandothercancers.ThiscompoundhasaveryhighoralbioavailABIlity.
References
BallantyneAD,Garnock-JonesKP.Dabrafenib:FirstGlobalApproval.Drugs.2013Jul24.[Epubaheadofprint]PMID:23881668.
HuangT,KarsyM,ZhugeJ,etal.B-Rafandtheinhibitors:frombenchtobedside.JHematolOncol.2013Apr25;6:30.PMID:23617957.
KlinacD,GrayES,MillwardM,etal.Advancesinpersonalizedtargetedtreatmentofmetastaticmelanomaandnon-invasivetumormonitoring.FrontOncol.2013;3:54.PMID:23515890.
HauschildA,GrobJJ,DemidovLV,etal.DabrafenibinBRAF-mutatedmetastaticmelanoma:amulticentre,open-label,phase3randomisedcontrolledtrial.Lancet.2012Jul28;380(9839):358-65.PMID:22735384.
